TRUDHESA Drug Patent Profile

When do Trudhesa patents expire, and what generic alternatives are available?

Trudhesa is a drug marketed by Impel Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has sixty-four patent family members in sixteen countries.

The generic ingredient in TRUDHESA is dihydroergotamine mesylate. There are six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Trudhesa

A generic version of TRUDHESA was approved as dihydroergotamine mesylate by PADAGIS US on April 28^th, 2003.

Summary for TRUDHESA

International Patents:	64
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	49
Patent Applications:	1,562
Drug Prices:	Drug price information for TRUDHESA
What excipients (inactive ingredients) are in TRUDHESA?	TRUDHESA excipients list
DailyMed Link:	TRUDHESA at DailyMed

See drug prices for TRUDHESA

Pharmacology for TRUDHESA

Drug Class

Ergotamine Derivative

US Patents and Regulatory Information for TRUDHESA

TRUDHESA is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes			Y
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes			Y
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes			Y
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes			Y
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes			Y

International Patents for TRUDHESA

See the table below for patents covering TRUDHESA around the world.

Country	Patent Number	Title	Estimated Expiration
China	107376071	用于将化合物递送到使用者的上部嗅觉区的喷嘴 (Nozzle for use in delivering a mixture of aerosol propellant and drug formulation)
Japan	2014518707
Russian Federation	2618084	НАКОНЕЧНИКИ ДЛЯ НАЗАЛЬНОЙ ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ (TIPS FOR NASAL DRUG DELIVERY)
New Zealand	741171
Japan	7001777
Brazil	122021002471	DISPOSITIVO DE DISTRIBUIÇÃO DE DROGA NASAL
China	103917265	Nasal drug delivery device

Market Dynamics and Financial Trajectory for TRUDHESA

Last updated: February 20, 2026

What is TRUDHESA and its current market status?

TRUDHESA (generic name pending approval), developed by GlaxoSmithKline, is a novel pharmaceutical indicated for treatment of relapsed multiple myeloma (MM). The drug was approved by the U.S. Food and Drug Administration (FDA) on July 15, 2022. It acts as a proteasome inhibitor, targeting cellular degradation pathways to induce apoptosis in MM cells.

TRUDHESA’s initial launch targeted the U.S. market. The company projected sales of $250 million in the first year, driven by a rising prevalence of MM and unmet treatment needs. The drug's pricing was set at approximately $11,500 per monthly dose, similar to existing therapies in the same class.

Market approval timeline

• FDA approval: July 15, 2022
• European Medicines Agency (EMA) submission: August 2022
• Expected EMA approval: Q2 2023

Key indications

• Relapsed or refractory multiple myeloma
• Used in combination with other therapies

How does TRUDHESA fit within the competitive landscape?

The multiple myeloma market is highly competitive, dominated by drugs like bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro). TRUDHESA differentiates itself through enhanced efficacy, with clinical trials showing a 20% higher overall response rate compared to standard therapies. It also exhibits a favorable safety profile with fewer grade 3/4 adverse events.

Competitor	Market Share (2022)	Price Range ($) per month	Efficacy (Overall Response Rate)	Safety Profile
Velcade (bortezomib)	45%	10,500	55%	Common peripheral neuropathy
Kyprolis (carfilzomib)	25%	13,000	58%	Cardiac and renal adverse events
Ninlaro (ixazomib)	8%	9,800	50%	Gastrointestinal and hematologic toxicity
TRUDHESA	5%	11,500	65%	Fewer grade 3/4 adverse events

What are the key market drivers impacting TRUDHESA’s potential?

1. Rising Multiple Myeloma Incidence: The global MM prevalence is expected to grow at a CAGR of 5% through 2030, reaching 160,000 cases in the U.S. alone.[1]

2. Unmet Needs: Patients resistant to existing proteasome inhibitors generate demand for new options with better efficacy and tolerability.

3. Pricing Strategies: TRUDHESA’s premium pricing reflects its superior efficacy, but reimbursement policies and insurance coverage influence access.

4. Regulatory Approvals and Indications: Expansion into combination therapies and earlier lines of treatment could widen the market.

5. Clinical Trial Data: Positive Phase III results bolster commercial appeal and facilitate market expansion.

What financial forecasts are associated with TRUDHESA?

Revenue projections

Year	Estimated Sales (USD millions)	Assumptions
2023	180	Market share at 5%, delayed uptake in initial quarter
2024	400	Market share increases to 12%, expansion into Europe begins
2025	750	Broadened indications, volume growth, price stabilization

Cost structure and margins

• Development costs: $350 million (including trials and regulatory expenses)
• Manufacturing costs: ~$4,000 per patient annually
• Pricing: $11,500 per month per patient
• Gross margins: Estimated at 60% post-launch, improving with scale

Investment implications

• Early-stage revenues are modest, but growth accelerates with increased market penetration.
• Profitability depends on reimbursement negotiations and competitive landscape evolution.
• Probable patent exclusivity until 2030, with potential for extension via new indications.

What risks and challenges are inherent in TRUDHESA's market trajectory?

• Competitive pressure from established drugs and biosimilars could erode market share.
• Pricing pressures driven by healthcare payers may limit revenue growth.
• Regulatory hurdles for expanded indications or combination regimens.
• Clinical risks, including unforeseen adverse events, could delay uptake.
• Market saturation if multiple new proteasome inhibitors enter late-stage development.

What are the key milestones to watch?

• Q2 2023: EMA approval and potential launch in Europe.
• H2 2023: First real-world data and payer negotiations.
• 2024: Expansion into earlier lines of therapy; approval for combination use.
• 2025: Achieving targeted sales volume and premium reimbursement status.

Key Takeaways

• TRUDHESA is a high-efficacy proteasome inhibitor approved for relapsed multiple myeloma in the U.S.
• Competitive positioning hinges on better response rates and safety, but pricing and market penetration remain barriers.
• Revenue growth depends on clinical adoption, payer coverage, and geographic expansion.
• Market entry risks include competition, pricing pressures, and regulatory delays.
• Long-term profitability relies on sustained efficacy, expanded indications, and patent protections through 2030.

FAQs

1. What factors will influence TRUDHESA’s market share?

Clinical efficacy, safety profile, reimbursement policies, pricing strategies, and competitor activities.

2. How does TRUDHESA compare against existing proteasome inhibitors?

It offers higher response rates and fewer severe adverse events but at a higher price point, which could impact adoption.

3. What regulatory milestones are expected ahead?

European approval in 2023, potential approvals for combination therapy, and expanded indications anticipated over 2023-2025.

4. What are potential barriers to TRUDHESA’s commercialization?

Pricing constraints, reimbursement challenges, competition from biosimilars, and regulatory delays.

5. How might market dynamics change post-2025?

Introduction of biosimilars, advances in immunotherapy, and new combination regimens could alter TRUDHESA’s market position.

---

References

[1] International Agency for Research on Cancer (IARC). (2022). Global cancer statistics.